Global Glaucoma Therapeutics Market to Grow at a CAGR of 2.9% Through 2026

Rising prevalence of glaucoma and other visual impairments have led to an increase in the demand for therapeutic drugs to treat these conditions. Around one-tenth of the elderly population suffers from glaucoma, which is expected to increase with each passing year. Consequently, the demand for better therapy options for the treatment of glaucoma is expected to boost demand for therapeutics. On the back of these factors, the global glaucoma therapeutics market shall witness a gradual growth, at a CAGR of 2.9% during the forecast period (2020-2026).

For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=4775

Other generic drivers, such as a greater geriatric population pool, a rise in the diabetic population and higher healthcare spending and infrastructure shall boost market growth.

Key Takeaways of Global Glaucoma Therapeutics Market Study

  • Prostaglandins are anticipated to account for the maximum market share of the glaucoma therapeutics market. This is attributed to its increased adoption in first line glaucoma treatment. The drug reduces intraocular pressure (IOP) by increasing uveoscleral flow. Projections indicate a market share of more than two-fifth of the total glaucoma therapeutics market.

For critical insights on this market, request for methodology here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=4775

  • Combination medicines are becoming more prevalent for glaucoma treatment. Greater effectiveness of treatment over individual medications is a key growth driver for this segment. For example, the Rhopressa drug class, a combination formula developed by Aerie Pharmaceuticals, has been approved for usage in commercial glaucoma treatment. Projected CAGR for combination medicines is pegged at 4.7% during the forecast period.
  • Hospitals shall account for the majority of the share of glaucoma therapeutics between 2020 and 2026. Increasing number of patients coupled with the ability to provide optimum healthcare services are major growth drivers.
  • North America is set to remain a lucrative market for glaucoma therapeutics. Increased focus on research and development of therapeutic drugs and approvals of certain drug categories like Rhopressa are expected to leverage the region’s market share. Asia-Pacific is following close behind, with a projected CAGR of 3.2% during the forecast period. Introduction of new drugs like Travopost and Timolol are expected to invigorate Asia-Pacific’s market share.

glaucoma therapeutics market 02

For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/4775/S

Glaucoma therapeutics market segmentation

Fact.MR has studied the glaucoma therapeutics market with detailed segmentation on the basis of drug class, end-users and key regions.

Drug Class End-users Key Regions
Prostaglandins Hospitals North America
Beta Blockers Ophthalmic Clinics Europe
Alpha Agonists Ambulatory Surgical Centers Asia Pacific
Carbonic Anhydrase Inhibitors   Latin America
Combination Medications   Middle East & Africa


For comprehensive insights on this market adoption, ask an analyst here – https://www.factmr.com/connectus/sample?flag=AE&rep_id=4775

Combination Drugs; a Growth Lever for Market Players

The global glaucoma therapeutics market consists of the following market players: Allergan plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Santen Pharmaceuticals Co. Ltd., Valeant Pharmaceuticals, Inc. and Aerie Pharmaceuticals, Inc. Novartis AG’s Alcon division focuses on development of eye care products, such as Travatan, Simbrinza and Azarga. Allergan Plc., occupies the second position in the market, and include top selling brands like Lumigan, Alphagan, Ganfort and Combigan. More recently, the company also received an approval from the FDA to launch its DURYSTATM Biodegradable Sustained-Release Implant. This device is designed to reduce intraocular pressure in open-angle glaucoma or ocular hypertension patients.

Read More Trending and Similar Reports from Fact.MR – https://www.globenewswire.com/en/news-release/2019/06/26/1874492/0/en/Oncology-Small-Molecule-Drug-Sales-to-Inflate-in-Line-with-Growing-Preference-for-Easily-Absorbable-Effective-Oral-Treatments-Fact-MR.html

Explore Fact.MR’s Comprehensive Coverage on Healthcare Landscape

Medical Grade Silicone Market Forecast, Trend, Analysis & Competition Tracking – Global Market Insights 2020 to 2030: https://www.factmr.com/report/5439/medical-grade-silicone-market

Diabetes Diagnostics Market Forecast, Trend, Analysis & Competition Tracking – Global Market Insights 2020 to 2030: https://www.factmr.com/report/5446/diabetes-diagnostics-market

Dermatology Diagnostic Devices Market Forecast, Trend, Analysis & Competition Tracking – Global Market Insights 2020 to 2030: https://www.factmr.com/report/5453/dermatology-diagnostic-devices-market

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.


US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

Back to top button